Developmental pharmacogenetics: A general paradigm for application to neonatal pharmacology and toxicology

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 678-682

  Leeder, J S ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BETA GLUCURONIDASE; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; PARACETAMOL; PRASTERONE SULFATE; SULFATASE; SULFOTRANSFERASE 1A1;

ADRENAL CORTEX; BODY COMPOSITION; CONGENITAL MALFORMATION; DEVELOPMENTAL GENETICS; DEVELOPMENTAL STAGE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EXPOSURE; DRUG TARGETING; DRUG TRANSFORMATION; ENVIRONMENTAL EXPOSURE; GASTROSCHISIS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HEREDITY; HUMAN; NEONATOLOGY; NEWBORN; ONTOGENY; PANCREAS FUNCTION; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PLASMA PROTEIN BINDING; PREDICTION; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH ACID SECRETION; STOMACH EMPTYING; TOTAL BODY WATER; TOXICOKINETICS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ENVIRONMENTAL POLLUTANTS; FEMALE; GASTROSCHISIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PHENOLS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; RISK FACTORS;

EID: 70450270796     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.195     Document Type: Review

References (30)

1. Blumer, J.L. & Reed, M.D. Principles of neonatal pharmacology. In Neonatal and Pediatric Pharmacology 3rd edn. (eds. Yaffe, S.J. & Aranda, J.V.) 146-158 (Lippincott Williams and Wilkins, Philadelphia, 2005).
2. Rodriguez, W. et al. Improving pediatric dosing through pediatric initiatives: what have we learned. Pediatrics 121, 530-539 (2008).
3. CDC. Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects-United States, 2003. Morbid Mortal Weekly Rep. 56, 25-29 (2007).
4. Werler, M.M., Mitchell, A.A. & Shapiro, S. First trimester maternal medication use in relation to gastroschisis. Teratology 45, 361-367 (1992).
5. Werler, M.M., Sheehan, J.E. & Mitchell, A.A. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am. J. Epidemiol. 155, 26-31 (2002).
6. Torfs, C.P., Katz, E.A., Bateson, T.F., Lam, P.K. & Curry, C.J.R. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54, 84-92 (1996).
7. Werler, M.M., Mitchell, A.A., Hernandez-Diaz, S. & Honein, M.A. Use of over-the-counter medications during pregnancy. Am. J. Obstet. Gynecol. 193, 771-777 (2005).
8. Bessems, J.G. & Vermeulen, N.P. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31, 55-138 (2001).
9. Bock, K.W. et al. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem. Pharmacol. 45, 1809-1814 (1993).
10. Reiter, C. & Weinshilboum, R.M. Platelet phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen. Clin. Pharmacol. Ther. 32, 612-621 (1982).
11. Strassburg, C.P. et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50, 259-265 (2002).
12. Barker, E.V., Hume, R., Hallas, A. & Coughtrie, M.W.H. Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunochemical characterization of the hepatic, renal, and adrenal enzymes. Endocrinology 134, 982-989 (1994).
13. Duanmu, Z. et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre-and postnatal human liver. J. Pharmacol. Exp. Ther. 316, 1310-1317 (2006).
14. Miki, Y. et al. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J. Clin. Endocrinol. Metab. 87, 5760-5768 (2002).
15. Richard, K., Hume, R., Kaptein, E., Stanley, E.L., Visser, T.J. & Coughtrie, M.W.H. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung and brain. J. Clin. Endocrinol. Metab. 86, 2734-2742 (2001).
16. Adjei, A.A., Gaedigk, A., Simon, S.D., Weinshilboum, R.M. & Leeder, J.S. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res. Part A Clin. Mol. Teratol. 82, 155-165 (2008).
17. Adjei, A.A., Thomae, B.A., Prondzinski, J.L., Ecklof, B.W., Wieben, E.D. & Weinshilboum, R.M. Human estrogen sulfotransferase (SULT1E1) pharmacogenetics: gene resequencing and functional genomics. Br. J. Pharmacol. 139, 1373-1382 (2003).
18. Hebbring, S.J. et al. Human SULT1A1 gene: copy number diferences and functional implications. Hum. Mol. Genet. 16, 463-470 (2007).
19. Hildebrandt, M.A. et al. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem. Biophys. Res. Commun. 321, 870-878 (2004).
20. Nagar, S., Walther, S. & Blanchard, R.L. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol. Pharmacol. 69, 2084-2092 (2006).
21. Thomae, B.A., Rifki, O.F., Theobald, M.A., Ecklof, B.W., Wieben, E.D. & Weinshilboum, R.M. Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. J. Neurochem. 87, 809-819 (2003).
22. Chapin, R. et al. NTP-CERHR Expert Panel Report to the Reproductive and Developmental Toxicity of Bisphenol A. (2007).
23. Völkel, W., Colnot, T., Csanády, G.A., Filser, J.G. & Dekant, W. Metabolism and kinetics of bisphenol A in humans at low doses following oral administration. Chem. Res. Toxicol. 15, 1281-1287 (2002).
24. Kim, Y.H., Kim, C.S., Park, S., Han, S.Y., Pyo, M.Y. & Yang, M. Gender diferences in the levels of bisphenol A metabolites in urine. Biochem. Biophys. Res. Commun. 312, 441-448 (2003).
25. Hanioka, N., Naito, T. & Narimatsu, S. Human UDP- glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 74, 33-36 (2008).
26. Suiko, M., Sakakibara, Y. & Liu, M.C. Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases. Biochem. Biophys. Res. Commun. 267, 80-84 (2000).
27. Serón-Ferré, M. & Jafe, R.B. The fetal adrenal gland. Annu. Rev. Physiol. 43, 141-162 (1981).
28. Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T. & Kanakubo, Y. P-450 HFLa, a form of cytochrome P-450 purifed from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 262, 13534-13537 (1987). (Pubitemid 17144304)
29. Baulieu, E.E. & Dray, F.L. Conversion of 3H-dehydroepiandrosterone (3β-hydroxy-Δ5-androsten-17-one) sulfate to 3H-estrogens in normal pregnant women. J. Clin. Endocrinol. Metab. 23, 1298-1301 (1963).
30. Siiteri, P.K. & MacDonald, P.C. The utilization of circulating dehydroepiandrosterone sulfate for estrogen synthesis during human pregnancy. Steroids 2, 713-730 (1963).